<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC_11(10-11)_494-495</article-id>
<article-id pub-id-type="doi">10.15836/ccar2016.494</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
</article-categories>
<title-group>
<article-title>Control of dyslipidemia in patients undergoing outpatient cardiovascular rehabilitation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6426-6831</contrib-id><name><surname>Ivanu&#x0161;a</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<aff id="aff1"><label>1</label>Institute for Cardiovascular Prevention and Rehabilitation, Zagreb, <country>Croatia</country></aff>
<aff id="aff2"><label>2</label>Univesity of Rijeka School of Medicine, Rijeka, <country>Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Address for correspondence: Mario Ivanu&#x0161;a, Poliklinika za prevenciju kardiovaskularnih bolesti i rehabilitaciju, Dra&#x0161;kovi&#x0107;eva 13, HR-10000 Zagreb, Croatia. / Phone: +385-1-4612-290; Fax: +385-1-4612-343 / E-mail: <email xlink:href="mivanusa@gmail.com">mivanusa@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>11</month><year>2016</year></pub-date>
<volume>11</volume>
<issue>10-11</issue>
<fpage>494</fpage>
<lpage>495</lpage>
<history>
<date date-type="received"><day>03</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2016</year></date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>dyslipidemia</kwd><kwd>cardiovascular rehabilitation</kwd><kwd>cardiovascular risk factors</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><bold>Introduction:</bold> Even 1 of 4 patients discharged after acute coronary syndrome will suffer from a heart attack, stroke or cardiovascular (CV) death over the next five years. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) The risk of these events is highest during the first year from the initial CV event (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) and can be reduced by treatment in accordance with the guidelines and participation in the CV rehabilitation program. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) The full approach to the CV rehabilitation that encompasses the evaluation of the CV status, therapeutic education, non-pharmacological and pharmacological measures and cardiovascular training successfully reduces the present impact of risk factors. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) This paper aims to show the incidence of CV risk factors and controls of dyslipidemia in patients enrolled in the outpatient CV rehabilitation program and to compare the results with the available data.</p>
<p><bold>Patients and Methods:</bold> The data on patients enrolled in the outpatient CV rehabilitation program in the Institute for Cardiovascular Disease Prevention and Rehabilitation in Zagreb in 2015 that completed the program by 15th March 2016 were retrospectively analyzed. The frequency of elevated body mass index, dyslipidemia, hypertension, diabetes/glucose intolerance, active smoking, and frequency of administration of individual doses of statins as well as the control of dyslipidemia in patients taking hypolypemic drugs (target values of LDL cholesterol &lt;1.8 mmol) was showed.</p>
<p><bold>Results:</bold> 207 patients were included in the analysis. The value of BMI &#x2265; 25 kg/m<sup>2</sup> was recorded in 88.4%, dyslipidemia in 78.7%, and hypertension in 75.8% of them. Diabetes/glucose intolerance was recorded in 27.5%, while there was 13.5 active smokers at the time of conducing the outpatient CV rehabilitation programs. The results of the dyslipidemia control are shown in <xref ref-type="table" rid="t1"><bold>Table 1</bold></xref>.</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Control of dyslipidemia in patients enrolled in outpatient cardiac rehabilitation program.</title></caption>
<table frame="hsides" rules="groups">
<col width="73.69%"/>
<col width="13.16%"/>
<col width="13.15%"/>
<thead>
<tr>
<th valign="top" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"><bold>Dyslipidemia</bold></th>
<th valign="top" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"><bold>Number</bold></th>
<th valign="top" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"><bold>%</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt" scope="col"><italic>High-intensity statins</italic></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"></td>
</tr>
<tr>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt" scope="col">atorvastatin 40 &#x2013; 80 mg (135/157)</td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"></td>
</tr>
<tr>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt" scope="row">rosuvastatin 20 &#x2013; 40 mg (22/157)</td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt">157</td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt">75.8%</td>
</tr>
<tr>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt" scope="row"><italic>Standard dose of statins</italic></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt">33</td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt">15.9%</td>
</tr>
<tr>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt" scope="row"><bold>Total on statins</bold></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"><bold>190</bold></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt"><bold>91.8%</bold></td>
</tr>
<tr>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt" scope="row"><italic>Dyslipidemia control in patients on lipid-lowering medication, low-density lipoprotein &lt;1.8 mmol/L</italic></td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt">111</td>
<td valign="top" align="left" style="border-left: solid 0.75pt; border-top: solid 0.25pt; border-right: solid 0.75pt; border-bottom: solid 0.25pt">58.4%</td>
</tr>
</tbody></table></table-wrap>
<p><bold>Discussion and Conclusion:</bold> In patients undergoing the outpatient CV rehabilitation, there is a high prevalence of CV risk factors, as shown in the data previous published by the Institute. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) In comparison with the data on patients from the recently published study EUROASPIRE IV (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>), the prevalence of risk factors is identical, except for hypertension that is more common in Croatian patients (75.8% versus 45.0%). The frequency of administration of statins, particularly intensive statin therapy is high, while the control of dyslipidemia is much better than in the study EUROASPIRE IV (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) (58.4% versus 25.6%). Despite this, the LDL cholesterol values did not equal the desired therapeutic values in a great number of patients.</p>
</body>
<back>
<ref-list>
<title>Literature</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu-Assi</surname><given-names>E</given-names></name><name><surname>L&#x00F3;pez-L&#x00F3;pez</surname><given-names>A</given-names></name><name><surname>Gonz&#x00E1;lez-Salvado</surname><given-names>V</given-names></name><name><surname>Redondo-Di&#x00E9;guez</surname><given-names>A</given-names></name><name><surname>Pe&#x0144;a-Gil</surname><given-names>C</given-names></name><name><surname>Bouzas-Cruz</surname><given-names>N</given-names></name><etal/></person-group> <article-title>The Risk of Cardiovascular Events After an Acute Coronary Event Remains High, Especially During the First Year, Despite Revascularization.</article-title> <source>Rev Esp Cardiol (Engl Ed)</source>. <year>2016</year>;<volume>69</volume>(<issue>1</issue>):<fpage>11</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.rec.2015.06.015</pub-id><pub-id pub-id-type="pmid">26342640</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Authors/Task Force Members</collab><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><name><surname>Albus</surname><given-names>C</given-names></name><name><surname>Brotons</surname><given-names>C</given-names></name><name><surname>Catapano</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR).</article-title> <source>Eur J Prev Cardiol</source>. <year>2016</year>;<volume>23</volume>(<issue>11</issue>):<fpage>NP1</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1177/2047487316653709</pub-id><pub-id pub-id-type="pmid">27353126</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanu&#x0161;a</surname><given-names>M</given-names></name><name><surname>Naran&#x010D;i&#x0107; Skori&#x0107;</surname><given-names>K</given-names></name><name><surname>Glava&#x0161; Vra&#x017E;i&#x0107;</surname><given-names>S</given-names></name><name><surname>Kruhek Leonti&#x0107;</surname><given-names>D</given-names></name><name><surname>Heinrich</surname><given-names>M</given-names></name><name><surname>Ma&#x017E;uran Brklja&#x010D;i&#x0107;</surname><given-names>L</given-names></name><etal/></person-group> <article-title>Outpatient Cardiovascular Rehabilitation in Croatia.</article-title> <source>Cardiol Croat</source>. <year>2015</year>;<volume>10</volume>(<issue>1-2</issue>):<fpage>28</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.15836/ccar.2015.28</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heim</surname><given-names>I</given-names></name><name><surname>Leonti&#x0107;</surname><given-names>DK</given-names></name><name><surname>Jonke</surname><given-names>V</given-names></name><name><surname>Romcevi&#x0107;</surname><given-names>M</given-names></name><name><surname>Jembrek-Gostovi&#x0107;</surname><given-names>M</given-names></name><name><surname>Henezi</surname><given-names>I</given-names></name></person-group>. <article-title>Patients in cardiac rehabilitation programme--where we were in 1999 and where 10 years later.</article-title> <source>Coll Antropol</source>. <year>2012</year> Jan;<volume>36</volume> <supplement>Suppl 1</supplement>:<fpage>59</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.5671/ca.2012361s.59</pub-id><pub-id pub-id-type="pmid">22338748</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Jennings</surname><given-names>C</given-names></name><name><surname>Gyberg</surname><given-names>V</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Ryd&#x00E9;n</surname><given-names>L</given-names></name><etal/><collab>EUROASPIRE Investigators</collab></person-group>. <article-title>Amouyel P. Adverse Lifestyle Trends Counter Improvements in Cardiovascular Risk Factor Management in Coronary Patients.</article-title> <source>J Am Coll Cardiol</source>. <year>2015</year>;<volume>66</volume>(<issue>14</issue>):<fpage>1634</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.07.061</pub-id><pub-id pub-id-type="pmid">26429091</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotseva</surname><given-names>K</given-names></name><name><surname>De Bacquer</surname><given-names>D</given-names></name><name><surname>Jennings</surname><given-names>C</given-names></name><name><surname>Gyberg</surname><given-names>V</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Ryd&#x00E9;n</surname><given-names>L</given-names></name><etal/><collab>EUROASPIRE Investigators</collab></person-group>. <article-title>Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999-2013</article-title>. <source>Glob Heart</source>. <year>2016</year> Mar 16. pii: <fpage>S2211-8160(15)00295-1</fpage>. . [<comment>Epub ahead of print</comment>]<pub-id pub-id-type="doi">10.1016/j.gheart.2015.11.003</pub-id><pub-id pub-id-type="pmid">26994643</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
